Claire L. Harris spends much of her time researching Complement system, Factor H, Immunology, Innate immune system and Alternative complement pathway. Her Complement system research integrates issues from Proteases, Biochemistry, Binding site and Cell biology. Her biological study spans a wide range of topics, including Mutation, Molecular biology, Internal medicine and Complement factor B.
Her Immunology study focuses mostly on Inflammation and Complement. Her research in Inflammation tackles topics such as Disease which are related to areas like Drug development, Systemic inflammation, Immune defence and Genotype. Her Innate immune system research focuses on Classical complement pathway and how it connects with T cell, Complement receptor and Acquired immune system.
Her primary areas of investigation include Immunology, Complement system, Factor H, Cell biology and Alternative complement pathway. Her study in Immunology concentrates on Complement, Inflammation, Complement receptor, Classical complement pathway and Complement membrane attack complex. Claire L. Harris combines subjects such as Molecular biology, Innate immune system, Disease and Macular degeneration with her study of Complement system.
The study incorporates disciplines such as Drug development, Bioinformatics and Intensive care medicine in addition to Disease. Her Factor H study combines topics from a wide range of disciplines, such as Complement factor I, Complement factor B and CD46. As a part of the same scientific study, she usually deals with the Cell biology, concentrating on Decay-accelerating factor and frequently concerns with Complement receptor 1.
Her primary areas of study are Complement system, Macular degeneration, Complement, Disease and Factor H. She has researched Complement system in several fields, including Clusterin, Endosome and Cell biology. Claire L. Harris has included themes like Odds ratio, Alternative complement pathway, Lysosome, Fibrinogen and Immunology in her Macular degeneration study.
She interconnects Downregulation and upregulation and Peritoneal dialysis in the investigation of issues within Immunology. Her work deals with themes such as Drug development and Bioinformatics, which intersect with Disease. Her Factor H research is classified as research in Genetics.
Claire L. Harris focuses on Disease, Tissue homeostasis, Eculizumab, Complement system and Drug development. Her Tissue homeostasis research includes elements of Risk analysis, Clinical trial, Complement and Drug discovery. Claire L. Harris specializes in Complement system, namely Complement factor I.
Her Biomarker research is multidisciplinary, relying on both Inflammation and Immunology. CD46 is frequently linked to Factor H in her study. Her study in Factor H is interdisciplinary in nature, drawing from both Complement factor B and C4A.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
C3 glomerulopathy: consensus report
Matthew C. Pickering;Vivette D. D'agati;Carla M. Nester;Richard J. Smith.
Kidney International (2013)
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.
Elena Goicoechea de Jorge;Claire L. Harris;Jorge Esparza-Gordillo;Luis Carreras.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Complement, a target for therapy in inflammatory and degenerative diseases.
B. Paul Morgan;Claire L. Harris;Claire L. Harris.
Nature Reviews Drug Discovery (2015)
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Aled Clayton;Claire L. Harris;Jacquelyn Court;Malcolm D. Mason.
European Journal of Immunology (2003)
Dimerization of complement factor H-related proteins modulates complement activation in vivo
E. Goicoechea de Jorge;J. J. E. Caesar;T. H. Malik;M. Patel.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Complement: central to innate immunity and bridging to adaptive responses.
B. Paul Morgan;Kevin J. Marchbank;M. Paula Longhi;Claire L. Harris.
Immunology Letters (2005)
Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation
Rubén Martínez-Barricarte;Meike Heurich;Francisco Valdes-Cañedo;Eduardo Vazquez-Martul.
Journal of Clinical Investigation (2010)
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk
Meike Heurich;Ruben Martínez-Barricarte;Nigel J. Francis;Dawn L. Roberts.
Proceedings of the National Academy of Sciences of the United States of America (2011)
Complement therapeutics; history and current progress
B Paul Morgan;Claire L Harris.
Molecular Immunology (2003)
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Mark S. Cragg;Elisa S. Jansen;Michele Cook;Claire Harris.
Journal of Clinical Investigation (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: